JNJ-7446
/ J&J
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 18, 2026
JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for solid tumor indications
(AACR 2026)
- "Abstract is embargoed at this time."
ADC • Late-breaking abstract • Preclinical • Oncology • Solid Tumor • EGFR
February 18, 2026
95437446LUC1001: A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors
(clinicaltrialsregister.eu)
- P1 | N=52 | Recruiting | Sponsor: Janssen Cilag International
New P1 trial • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
December 06, 2025
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
(clinicaltrials.gov)
- P1 | N=380 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Nov 2027 ➔ Apr 2028
Trial completion date • Colorectal Cancer • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1